Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 29th, 2017, John Szydlo notified Cleveland Biolabs, Inc. (the “Company”) that he will resign as the Company’s Principal Financial Officer, effective June 16, 2017, in order to accept a senior executive position at another company. Following Mr. Szydlo’s resignation, Yakov Kogan, the Company’s Chief Executive Officer, will serve as the interim Principal Financial Officer, effective June 16th, while the Company searches for a replacement for Mr. Szydlo. Information regarding Dr. Kogan’s background and business experience, contracts between the Company and Dr. Kogan and any related party transactions involving Dr. Kogan is incorporated by reference herein from the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 3, 2017. Mr. Szydlo will continue to be employed by the Company to assist with the transition of his duties for a period of approximately one week after the effective date of his resignation from the office of Principal Financial Officer. Mr. Szydlo’s decision to resign was not due to any disagreement relating to the Company’s management, policies, or practices.
About Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5. Cleveland BioLabs, Inc. (NASDAQ:CBLI) Recent Trading Information
Cleveland BioLabs, Inc. (NASDAQ:CBLI) closed its last trading session down -0.09 at 3.95 with 281,896 shares trading hands.
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5. Cleveland BioLabs, Inc. (NASDAQ:CBLI) Recent Trading Information
Cleveland BioLabs, Inc. (NASDAQ:CBLI) closed its last trading session down -0.09 at 3.95 with 281,896 shares trading hands.